Press release
Migraine Drugs Market Deep Dive: Pipeline Breakthroughs & Market Potential | Top 5 Companies are Eli Lilly and Company, AbbVie Inc, Pfizer Inc, Lundbeck, Impel Pharmaceuticals Inc
Migraine Drugs Market
United States Migraine Drugs Market size in 2024: USD 3.15 B and projection to USD 5.44 B by 2032 with a CAGR 7.3% (2025-2032)
Japan Migraine Drugs Market size in 2024: USD 0.44 B and projection to USD 0.66 B by 2032 with a CAGR 4.6% (2025-2032)
United States: Recent Industry Developments
✅ October 2025: AbbVie advanced its CGRP-inhibitor portfolio with new clinical data supporting improved efficacy in chronic migraine treatment.
✅ September 2025: FDA cleared a next-gen oral migraine medication offering faster onset relief for acute attacks.
✅ August 2025: Biotech firms expanded research into personalized migraine therapies using AI-driven patient profiling.
Japan: Recent Industry Developments
✅ October 2025: Otsuka Pharmaceutical introduced new migraine prevention therapies tailored to patients with high-frequency migraine episodes.
✅ September 2025: Japanese researchers reported positive trial results for novel CGRP-targeting biologics.
✅ August 2025: Pharma-clinic collaborations grew to enhance early diagnosis and treatment pathways for migraine patients.
Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/migraine-drugs-market?kb
Migraine treatment costs vary widely. OTC options like Excedrin and Advil Migraine are inexpensive for occasional migraines, while chronic cases often require prescription triptans, CGRP pills, or CGRP monoclonal antibodies. Prices range from about $10 for sumatriptan to over $1,000 for eptinezumab.
Latest M&A Activity
Pfizer acquired Biohaven Pharmaceuticals in a deal valued over $11 billion expanding its migraine portfolio with drugs like Nurtec (rimegepant) and Zavzpret (zavegepant), both CGRP receptor antagonists for acute and preventive migraine treatment.
Tonix Pharmaceuticals acquired sumatriptan nasal spray and injectable migraine treatments from Upsher-Smith for $23 million, bolstering its migraine drug pipeline with established therapies.
Key Players:
Amgen Inc, Tonix Pharmaceuticals, Teva Pharmaceuticals, Eli Lilly and Company, AbbVie Inc, Pfizer Inc, Lundbeck, Impel Pharmaceuticals Inc, Currax Pharmaceuticals, Endo Pharmaceuticals Inc
Growth Forecast Projected:
The Global Migraine Drugs Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
Research Process:
Both primary and secondary data sources have been used in the global Migraine Drugs Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @: https://www.datamintelligence.com/buy-now-page?report=migraine-drugs-market?kb
Key Segments:
By Drug Class: (NSAIDs, Acetaminophen, CGRP Monoclonal Antibodies, CGRP Small Molecule Antagonists, Acetylcholine Inhibitors/ neurotoxins, Triptans, Antidepressants, Ergot alkaloids, Others)
By Route of Administration: (Oral, Injectable, Others)
By Age Group: (Pediatric, Adult, Geriatric)
By Distribution Channel: (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
Regional Analysis for Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Recent FDA Approvals and Product Launches
In January 2025, Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) was approved by the FDA for acute migraine with or without aura. It offers rapid relief and sustained efficacy for up to 48 hours, available as a single-dose oral medication.
Pfizer launched Rimegepant orally disintegrating tablet (ODT) in India for adults with insufficient response to triptans, providing rapid and sustained pain relief with a reduced risk of medication overuse headaches.
Amneal Pharmaceuticals launched Brekiya® (dihydroergotamine mesylate) autoinjector for acute migraine and cluster headache treatment in the US in October 2025, the first ready-to-use DHE autoinjector approved for these indications
Get Customization in the report as per your requirements: https://datamintelligence.com/customize/migraine-drugs-market?kb
Clinical Trials
Phase 3 trial data for UBROGEPTAN confirm its efficacy in addressing non-headache-related symptoms of migraines like nausea and light sensitivity, reinforcing its use for migraine management.
Fremanezumab (Ajovy) showed clinical benefits for patients with migraine and comorbid depressive disorder in a 28-week study, pointing to multi-symptom relief potential.
Multiple ongoing trials investigate next-gen CGRP antagonists, gepants in various formulations, and combination therapies aimed at personalized migraine care.
Get 2-Day Free Trial + 50% OFF DataM Subscription@: https://www.datamintelligence.com/reports-subscription?kb
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Migraine Drugs Market Deep Dive: Pipeline Breakthroughs & Market Potential | Top 5 Companies are Eli Lilly and Company, AbbVie Inc, Pfizer Inc, Lundbeck, Impel Pharmaceuticals Inc here
News-ID: 4279967 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
United States Blockchain in Agriculture Market is to reach USD 5.57 billion by 2 …
Global Market reached US$ 352.56 million in 2024 and is expected to reach US$ 5,570.71 million by 2032, growing with a CAGR of 41.20% during the forecast period 2025-2032.
Download Free sample report:-https://www.datamintelligence.com/download-sample/blockchain-in-agriculture-market?pratik
Recent Industry Development in U.S market:
✅US Blockchain in Agriculture Market: USD 352.56 million in 2024; projected USD 5.57 billion by 2032.
✅Major U.S. companies like IBM and Microsoft are active in this space, offering blockchain platforms for traceability,…
Rolled Aluminum Products Market to Reach USD 102.21 Billion by 2031, Driven by D …
The Rolled Aluminum Products Market reached US$ 60.81 billion in 2024 and is projected to grow to US$ 102.21 billion by 2031, registering a CAGR of 7.7 percent during the forecast period. Growth is driven by increasing demand for lightweight, recyclable, and high-performance materials across automotive, aerospace, construction, and packaging industries.
The market holds a strong position as a core material segment supporting global manufacturing and sustainability goals. Rolled aluminum products,…
US Mice Model Market Projected to Grow at 6.16% CAGR from 2025 to 2034, Supporte …
Leander, Texas and TOKYO, Japan - The United States Mice Model Market is valued at approximately USD 6.55 billion in 2024 and is projected to reach about USD 11.91 billion by 2034, growing at a CAGR of around 6.16% during the forecast period from 2025 to 2034.
This growth is driven by advancements in gene editing tools, increased demand for humanized mice models, physiological similarities between humans and mice, and rising…
Agave Inulin Market Growing at 4.2% CAGR During 2023-2030 Forecast | Food & Beve …
Leander, Texas and Tokyo, Japan - Nov 20, 2025
According to DataM Intelligence, the global agave inulin market is growing at a CAGR of 4.2% during the forecast period (2023-2030). This steady growth is propelled by increasing consumer preference for natural sweeteners, rising health consciousness driving demand for prebiotic fibers, growing applications in functional food and beverages, expanding pharmaceutical uses, and continuous product innovations enhancing functionality and application range.
Get a…
More Releases for Migraine
Leading Growth Driver in the Migraine Market Share in 2025: Rising Prevalence Of …
What Market Share dynamics are playing a key role in accelerating the growth of the migraine Market Share?
The migraine Market Share is projected to grow, driven by the rising occurrence of migraines. Migraines, a kind of headache that typically affects one side of the brain and causes intense, throbbing pain or a pulsing sensation, can be managed and relief can be provided via proper treatment. This treatment paves the way…
Emerging Acute Migraine Treatment Market Trend 2025-2034: Innovative CGRP Recept …
How Is the Acute Migraine Treatment Market Projected to Grow, and What Is Its Market Size?
The market size for acute migraine treatment has witnessed substantial growth in the past few years. Forecasts expect it to expand from $2.6 billion in 2024 to $2.91 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth in the historical period include the rising incidence of migraines,…
Key Influencer in the Migraine Market 2025: Rising Prevalence Of Migraine Drives …
"What Is the Forecasted Market Size and Growth Rate for the Migraine Market?
The migraine market is projected to grow steadily from $1.93 billion in 2024 to $1.97 billion in 2025, at a CAGR of 2.2%. This growth is attributed to the rising prevalence of migraines, growing awareness of treatment options, government initiatives, increased alcohol consumption, and lifestyle changes.
Migraine Market: Expected to grow to $2.25 billion by 2029 at a CAGR…
How Big is Migraine Drugs Market?
In 2022, the Global Migraine Drugs Market soared to USD 10,972.1 million, marking a significant milestone. Projections indicate a promising trajectory, with expectations set for substantial growth, potentially reaching USD 26,618.96 million by 2031. Forecasts for the period between 2024 and 2031 suggest a robust Compound Annual Growth Rate (CAGR) of 12.1% for the migraine drugs market.
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive…
Migraine Therapeutics Market - Relieve the Burden: Empowering Lives through Migr …
Newark, New Castle, USA - new report, titled Migraine Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Migraine Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Migraine Therapeutics market. The report offers an overview of the market, which…
Rise in Prevalence of Migraine Drives the Migraine Drugs Market | Outlook 2025
Migraine is characterized by a recurrent throbbing headache, which affects only one side of the head. It is accompanied by vomiting, nausea and even altered vision in some cases.
The increase in the prevalence of migraine, the rapid increase in the female population and the increased awareness among patients for the treatment and prevention of migraine are driving the growth of the global market for anti-migraine drugs.
Get Access to TOC /…
